Arvinas Inc
NASDAQ:ARVN

  • LAST PRICE
    26.3100
  • TODAY'S CHANGE (%)
    -1.7300 (-6.1698%)
  • Bid / Lots
    20.0000/ 5
  • Ask / Lots
    27.0000/ 5
  • Open / Previous Close
    27.5800 / 28.0400
  • Day Range
    24.9200
    27.7600
  • 52 Week Range
    14.6400
    53.0800
  • Volume
    846,864

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ARVN
Arvinas Inc
1.9B
-5.5x
---
NRIX
Nurix Therapeutics Inc
2.0B
-9.3x
---
NTLA
Intellia Therapeutics Inc
1.8B
-3.1x
---
TARS
Tarsus Pharmaceuticals Inc
1.9B
-10.7x
---
VRDN
Viridian Therapeutics Inc
2.0B
-5.3x
---
RXRX
Recursion Pharmaceuticals Inc
2.2B
-4.9x
---
As of 2024-11-12

Company Information

Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.

Contact Information

Headquarters
5 Science ParkNEW HAVEN, CT, United States 06511-1966
Phone
203-535-1456
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
John Houston
Chief Financial Officer, Treasurer
Andrew Saik
President - Research and Development
Ian Taylor
Chief Scientific Officer
Angela Cacace
General Counsel
Jared Freedberg

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.9B
Revenue (TTM)
$161.1M
Shares Outstanding
68.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.85
EPS
$-4.79
Book Value
$9.71
P/E Ratio
-5.5x
Price/Sales (TTM)
12.0
Price/Cash Flow (TTM)
---
Operating Margin
-221.85%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.